The company manufactures knitted apparel and trades fabrics, primarily serving the domestic Indian retail market through a network of wholesalers and distributors.
The company operates in a highly fragmented and commodity-like garment sector with no evidence of brand power or cost advantage. Net margins of 1.7% and a negative cash conversion cycle indicate a lack of pricing power and weak bargaining position with customers.
Capital is primarily tied up in working capital and related-party transactions. The company recently initiated a large rights issue to fund working capital, suggesting an inability to generate sufficient internal cash flow for operations.
The business succumbed to a slow-motion liquidation of shareholder value as the thin 1.7% net margins were entirely consumed by rising working capital requirements and persistent related-party leakages. Despite management's promotional narrative, the stagnant revenue growth proved that the company lacked any brand pull, while the reliance on rights issues to fund basic operations eventually exhausted investor patience. The failure was finalized when the negative cash conversion cycle and GST litigation liabilities forced a liquidity crunch that the promoter-controlled entities refused to bridge, leaving minority shareholders with a hollowed-out shell.
RichFakir rates Garment Mantra Lifestyle Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Garment Mantra Lifestyle Ltd is trading about 7% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Garment Mantra Lifestyle Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Garment Mantra Lifestyle Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →